Navigation Links
Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
Date:10/23/2008

with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... St. Louis, MO (PRWEB) May 21, 2015 ... that assesses the safety and efficacy of pharmaceutical products ... Access Drive Maryland Heights, MO 63043, a 50,000 sq. ... their current location, to enable strategic growth. Facility renovations ... offices to the new space will occur in September. ...
(Date:5/21/2015)... -- Prima Biomed Ltd. (NASDAQ: PBMD ) a globally ... leader in the development of immunotherapeutic products for the ... data from the Phase II CAN-003 ovarian cancer clinical ... meaningful improvement in Overall Survival ("OS") over standard of ... the group of second remission patients (n=20), the median ...
(Date:5/21/2015)... LONDON , May 21, 2015 ... your inner feelings - and those of others. Being ... and senses. Analyze and read people to anticipate their ... your deepest emotions and feelings to create unique ... generation of responsive games. Get inside a first-person-shooter as ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
Breaking Biology Technology:Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... Ikaria, Inc., a critical care company focused on developing and ... critically ill patients in the hospital and ICU settings, today ... at the 14th Annual BIO CEO & Investor Conference.  Mr. ... at 3:30 p.m. EST in the Park South of the ...
... this week in Science , a Manchester team lead ... has literally opened a third dimension in graphene research. Their ... for graphene to become the next silicon. Graphene ... material with endless unique properties, from electronic to chemical and ...
... (NASDAQ: ITMN ) today announced that it will ... at the close of the U.S. markets on Thursday, February ... hosted by InterMune at 4:30 p.m. Eastern time that same ... the conference call by dialing 800-891-8257 (U.S.) or +1-212-271-4651 (international), ...
Cached Biology Technology:Ikaria® to Present at 14th Annual BIO CEO & Investor Conference 2Graphene electronics moves into a third dimension 2InterMune to Release Fourth Quarter and Full Year Financial Results on February 9 2
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
(Date:5/11/2015)... May 11, 2015  Through a well-rounded UAS delegation representing ... had a strong showing at AUVSI,s Unmanned 2015 conference last ... Ohio,s UAS industry met with over ... all points along the UAS ecosystem. "Our ... Vice President for Aerospace Rich Knoll . "If you ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... developed a 3D filming technique that could help inform research ... digital holograms of malaria sperm has given researchers fresh insights ... Understanding how malaria parasites mate could pave the way ... poses a threat to half of the world,s population. ...
... This news release is available in German . ... assess the global impacts of land use on the environment ... the leadership of the Helmholtz Centre for Environmental Research (UFZ) ... Based on various indicators of land-use intensity, climate, environmental and ...
... Awards acknowledges projects that aim for the development ... the awards distinguished with honorable mentions the Initiative ... tracks Mobilization Initiative of Sic Notcias and Information ... collaborations with MIT Portugal Program, in partnership with ...
Cached Biology News:Global map provides new insights into land use 2Global map provides new insights into land use 3MIT Portugal is a partner of 2 projects distinguished by the Green Project Awards 2
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
... FP Standardization Kit is used to ... polarization values of fluorescein solutions to ... System. It also allows users to ... their instrument to the expected values ...
Biology Products: